(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Division of Clinical Pharmacology’s mission is to conduct and support investigator-initiated clinical studies to promote and enhance the development, rational use and individualization of new and existing drug therapies in neonates, infants, children, adolescents and young adults.
Our faculty conducts clinical, translational and basic research that helps clinicians increase drug efficacy and reduce toxicity by optimizing drug selection and individualizing drug dosing. In addition, division members provide multimodality clinical pharmacology teaching and training that enhances the knowledge of residents, fellows and faculty.
We also provide inpatient and outpatient clinical consultation to improve rational therapy using therapeutic drug management (TDM) and pharmacogenetic testing. The Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management offers services to patients with recurrent sub- or super-therapeutic drug concentrations or drug treatment failures.
Research That Leads to ResultsResearch interests include pharmacogenetics, population pharmacokinetic-pharmacodynamic (PK / PD) analysis and modeling (pharmacometrics), as well as clinical trial design and simulation. As part of the Genetic Pharmacology Service, the division is investigating new methods to reduce adverse reactions by identifying genetic variations in drug metabolism, providing dose recommendations based on the patient’s drug metabolizing genotype / phenotype and delineating clinically significant drug interactions. The goal of these studies is to:
We Want Safe Medication for ChildrenThe need for pharmacology research has never been greater − a fact that was illustrated with the recall of children’s cough and cold medicines. During the past 10 years, Congress and the National Institutes of Health (NIH) have made it clear that safe drug therapy for children is a priority. Congress passed the Best Pharmaceuticals for Children Act (BPCA) and it was signed in 2002 to establish a process for studying on-patent and off-patent drugs for use in pediatric populations. Our program promotes BPCA efforts and responds to other demands for pediatric clinical drug studies, including those by the Food and Drug Administration (FDA) Modernization Act and the FDA 1998 Pediatric Rule.
Important Facts about Medications and Children
Learn more about how we’re using pharmacogenetics − the study of drug interactions with an individual’s genetic makeup – to improve patient safety and to help physicians choose the right dose.
Click to view members
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center